Form 4 for TBPH Theravance Biopharma, Inc.
Accepted 2024-04-04 00:00:00 ET · period of report 2024-04-02 · accession 0001415889-24-010328 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-04-04 | 2024-04-02 | TBPH | Winningham Rick E | CEO, Dir | A - Grant | $0.00 | +300.0K | 1.85M | +19% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2024-04-02 | A | A | 300,000 | $0.00 | 1,850,573 | D | — | — | (F1) On April 2, 2024, the reporting person was granted 300,000 RSUs. 150,000 RSUs are subject to service-based vesting conditions and the remaining 150,000 RSUs vest based on the achievement of share price appreciation targets as well as continued employment. |